Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis

Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis 1 / 2 Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis A pharmacist holds a bottle of the drug Eliquis, made by Pfizer Pharmaceuticals, at a pharmacy in Provo, Utah, U. S. January 9, 2020.

REUTERS/George Frey Reuters Tue, August 4, 2026 at 12:58 PM GMT+2 1 min read PFE Aug 4 (Reuters) - Pfizer on Tuesday slightly raised the lower end of ‌its full-year revenue forecast after ‌beating Wall Street estimates for second-quarter profit, driven ​by strong demand for blood thinner Eliquis. Shares rose 1. 8% to $25.

5 in premarket trading. Pfizer is banking on newer medicines to offset ‌fading COVID revenue ⁠and reduce reliance on aging blockbuster drugs, while investors look ⁠for signs that its $10 billion purchase of Metsera can help establish a meaningful ​presence in ​the fast-growing ​obesity market. The drugmaker, whose ‌shares have fallen more than 50% from their pandemic-era peak, expects to return to stronger growth after 2028.

The U. S. drugmaker now expects annual sales of $60.

5 ‌billion to $62. 5 billion, up ​from $59. 5 billion to $62.

5 billion ​forecast previously. On ​an adjusted basis, the company ‌reported a profit of ​77 cents ​per share, compared with analysts' estimates of 68 cents per share, according ​to data ‌compiled by LSEG.